- Trials with a EudraCT protocol (787)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
787 result(s) found for: Plasma volume.
Displaying page 8 of 40.
EudraCT Number: 2012-005796-14 | Sponsor Protocol Number: 1/2013 | Start Date*: 2014-05-13 |
Sponsor Name:Medizinische Universität Wien | ||
Full Title: A randomized, pilot study to assess the impact of single nucleotide polymorphisms in the ABCB1 and ABCG2 genes on brain and organ distribution of dual Pgp/BCRP substrates in humans. | ||
Medical condition: The effect of genetic polymorphisms on drug distribution will be investigated in healthy volunteers | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: AT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2014-003403-29 | Sponsor Protocol Number: TMP-SMT-CVVH | Start Date*: 2014-09-26 |
Sponsor Name:Innsbruck Medical University | ||
Full Title: Pharmacokinetics of trimethoprim-sulfametrole in critically ill patients on continuous veno-venous haemofiltration | ||
Medical condition: Life-threatening infection treated with trimethoprim-sulfametrole (Rokiprim) in critically ill patients on and off continuous veno-venous haemfiltration | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-017823-24 | Sponsor Protocol Number: 1703 | Start Date*: 2010-03-19 |
Sponsor Name:Tartu University Hospital | ||
Full Title: Meropenem pharmacokinetics in very low birth weight neonates | ||
Medical condition: proven or suspected sepsis, lower respiratory tract infection, complicated intraabdominal infection | ||
Disease: | ||
Population Age: Preterm newborn infants, Newborns, Under 18 | Gender: Male, Female | |
Trial protocol: EE (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-003532-39 | Sponsor Protocol Number: SitaBAT01 | Start Date*: 2014-11-24 |
Sponsor Name:Leiden University Medical Center | ||
Full Title: The effect of sitagliptin on brown adipose tissue and whole-body metabolism in overweight pre-diabetic men | ||
Medical condition: Obesity, dyslipidemia and impaired glucose tolerance | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-002295-40 | Sponsor Protocol Number: 08-06-2018-paracet | Start Date*: 2018-09-11 |
Sponsor Name:Copenhagen Neuromuscular Center | ||
Full Title: Pharmacokinetics and safety of treatment with paracetamol in children and adults with spinal muscular atrophy and cerebral palsy | ||
Medical condition: Spinal muscular atrophy type II (SMA II) Cerebral palsy (CP) | ||
Disease: | ||
Population Age: Children, Under 18, Adults | Gender: Male, Female | |
Trial protocol: DK (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2016-001878-15 | Sponsor Protocol Number: E3810-A001-119 | Start Date*: 2016-06-27 |
Sponsor Name:Eisai Medical Research Inc. | ||
Full Title: Single and Multiple Dose Pharmacokinetics and Safety Study of Rabeprazole Sodium in 12 to 16 Year Old Subjects | ||
Medical condition: Gastroesophageal Reflux Disease (GERD) | ||
Disease: | ||
Population Age: Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2018-002715-10 | Sponsor Protocol Number: FAR-NP-2018-01 | Start Date*: 2019-02-08 |
Sponsor Name:Elisabet Leiva Badosa. Phamacy Department. Hospital Universitari de Bellvitge | ||
Full Title: RANDOMIZED, DOUBLE-BLIND, PILOT CLINICAL TRIAL TO COMPARE THE EFFICACY AND SAFETY OF FISH OIL-BASED INTRAVENOUS LIPID EMULSIONS IN HOSPITALIZED ADULT PATIENTS TREATED WITH TOTAL PARENTERAL NUTRITIO... | ||
Medical condition: Hypertriglyceridemia is a frequent metabolic complication associated with the administration of lipidic emulsion in total parenteral nutrition. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2019-003137-42 | Sponsor Protocol Number: EPIFLUX | Start Date*: 2020-04-10 |
Sponsor Name:Medizinische Universität Wien, Universitätsklinik für Klinische Pharmakologie | ||
Full Title: Exploring P-glycoprotein-mediated efflux transport at the blood-brain barrier as a biomarker of drug-resistance in focal epilepsy | ||
Medical condition: Investigation in healthy volunteers and epilepsy patients | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2010-023003-96 | Sponsor Protocol Number: BAY86-4875/91741 | Start Date*: 2012-04-25 |
Sponsor Name:Bayer HealthCare AG | ||
Full Title: Open-label, multicenter, pharmacokinetic, and safety study in children (term newborn infants to 23 months of age) undergoing a contrast-enhanced MRI with an intravenous injection of 0.1 mmol/kg BW ... | ||
Medical condition: Pediatric subjects aged <2 years (term newborn infants to toddlers 23 months of age inclusive) scheduled to undergo routine gadolinium-enhanced MRI of any body region | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-006287-50 | Sponsor Protocol Number: EMAOS | Start Date*: 2015-04-01 | |||||||||||
Sponsor Name:Clínica Universidad de Navarra/Universidad de Navarra | |||||||||||||
Full Title: Phase III comparative clinical trial to evaluate the efficacy of amniotic membrane extract for the treatment of severe dry eye disease, in comparison with autologous serum eyedrops. | |||||||||||||
Medical condition: Severe Dry Eye Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000010-38 | Sponsor Protocol Number: PAEDMED_v1.0 | Start Date*: 2018-03-20 |
Sponsor Name:Department of Clinical Pharmacology/Medical University of Vienna | ||
Full Title: Development of intravascular microdialysis as a tool for therapeutic drug monitoring in children. | ||
Medical condition: cohort A: We will administer a single dose of vancomycin, cefuroxime or gentamicin to healthy volunteers. The administration of the antibiotics in cohort A is for study purposes only. cohort B: We... | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Under 18, Adults | Gender: Male, Female | |
Trial protocol: AT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2016-002904-15 | Sponsor Protocol Number: B9991011 | Start Date*: 2017-05-18 | |||||||||||
Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: PHASE 1B/PHASE 3 MULTICENTER STUDY OF AVELUMAB (MSB0010718C) IN COMBINATION REGIMENS THAT INCLUDE AN IMMUNE AGONIST, EPIGENETIC MODULATOR, CD20 ANTAGONIST AND/OR CONVENTIONAL CHEMOTHERAPY IN PATIEN... | |||||||||||||
Medical condition: Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Prematurely Ended) SE (Completed) CZ (Prematurely Ended) GB (Completed) ES (Completed) DK (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002195-27 | Sponsor Protocol Number: AC101 | Start Date*: 2016-07-08 |
Sponsor Name:University of Tartu | ||
Full Title: Pharmacokinetics and tissue penetration of amoxicillin/clavulanic acid in patients with sepsis and septic shock | ||
Medical condition: Sepsis and septic shock | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: EE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2013-001900-13 | Sponsor Protocol Number: D4280C00014 | Start Date*: 2013-06-05 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Phase I Study to Assess the Pharmacokinetics, Safety and Tolerability of a Single Dose of Ceftazidime-Avibactam (CAZ-AVI) in Children From 3 Months of Age to <18 Years Who Are Receiving Systemic ... | |||||||||||||
Medical condition: hospitalized pediatric patients receiving systemic antibiotic therapy for suspected or confirmed infection. | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001160-29 | Sponsor Protocol Number: SH-NEC-0002 | Start Date*: 2012-03-08 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: An Open Single-centre Study on the Pharmacokinetics and Pharmacodynamics of Esomeprazole After Once Daily Oral Administration for 7 Days in Preterm Infants and Neonates | |||||||||||||
Medical condition: Gastraesdophageal Reflux Disease | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Newborns, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-000415-32 | Sponsor Protocol Number: DAL-PK-02 | Start Date*: 2022-06-07 | |||||||||||
Sponsor Name:Allergan | |||||||||||||
Full Title: Pharmacokinetics of a Single-Dose of Dalbavancin in Preterm Neonates to Infants Ages 3 Months With Suspected or Confirmed Bacterial Infection | |||||||||||||
Medical condition: Bacterial Infection in hospitalized children | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-007862-39 | Sponsor Protocol Number: BE1116_3003 | Start Date*: 2009-01-16 | ||||||||||||||||
Sponsor Name:CSL Behring GmbH | ||||||||||||||||||
Full Title: An open-label, randomized, multicenter Phase IIIb study to assess the efficacy, safety and tolerance of BERIPLEX® P/N compared with plasma for rapid reversal of coagulopathy induced by vitamin K an... | ||||||||||||||||||
Medical condition: Perioperative prophylaxis for emergency surgery in subjects who have an acquired deficiency of vitamin K-dependent coagulation factors and proteins C and S | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BG (Completed) PL (Prematurely Ended) IT (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-004831-11 | Sponsor Protocol Number: MEDI4736-MM-002 | Start Date*: 2016-05-17 | |||||||||||
Sponsor Name:Celgene International II Sàrl | |||||||||||||
Full Title: A Phase 1/2, multicenter, open-label study to determine the recommended dose and regimen of durvalumab (MEDI4736) in combination with lenalidomide (LEN) with and without dexamethasone (dex) in subj... | |||||||||||||
Medical condition: Newly diagnosed multiple myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Temporarily Halted) DK (Completed) FI (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-017595-25 | Sponsor Protocol Number: 04-AnIt-09/UKM09_0031 | Start Date*: 2011-02-22 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:University Hospital Muenster | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: Balanced 6 % HES 130/0.4 vs. balanced crystalloid-based infusion in patients undergoing colorectal surgery | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Patients undergoing colorectal surgery | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-003314-24 | Sponsor Protocol Number: CC-10004-PPSO-001 | Start Date*: Information not available in EudraCT | ||||||||||||||||
Sponsor Name:Celgene Corporation | ||||||||||||||||||
Full Title: A Phase 2, Multicenter, Open-label Study to Assess the Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects with Moderate to Severe Plaque Psoriasis | ||||||||||||||||||
Medical condition: Moderate to severe plaque psoriasis in adolescents (ages 12 to 17 years, inclusive) and in children (ages 6 to 11 years, inclusive). | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) DE (Completed) ES (Completed) Outside EU/EEA | ||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
